MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Gilead Sciences Inc.

Suletud

SektorTervishoid

106.04 -0.46

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

105.83

Max

107.54

Põhinäitajad

By Trading Economics

Sissetulek

530M

1.8B

Müük

29M

7.6B

P/E

Sektori keskmine

274.553

57.333

Aktsiakasum

1.9

Dividenditootlus

3.02

Kasumimarginaal

23.557

Töötajad

17,600

EBITDA

-655M

3.1B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+9.79% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.02%

2.63%

Järgmine dividendimakse kuupäev

26. juuni 2025

Järgmine aktsia dividendi kuupäev (ex-date)

13. juuni 2025

Turustatistika

By TradingEconomics

Turukapital

8.7B

130B

Eelmine avamishind

106.5

Eelmine sulgemishind

106.04

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Gilead Sciences Inc. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2025, 20:17 UTC

Tulu

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

11. veebr 2025, 21:17 UTC

Tulu

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

24. apr 2025, 20:08 UTC

Tulu

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences 1Q Rev $6.67B >GILD

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences: During 1Q Generated $1.8 Billion in Operating Cash Flow >GILD

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences: 1Q Lower Veklury (Remdesivir) and Oncology Sales Offset by Higher HIV and Liver Disease Sales >GILD

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences Sees 2025 EPS $5.65-EPS $6.05 >GILD

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences 1Q EPS $1.04 >GILD

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences 1Q EPS $1.04 >GILD

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences Sees FY EPS $5.65-EPS $6.05 >GILD

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences 1Q Total Liver Disease Sales $758M >GILD

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences 1Q Net $1.32B >GILD

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences Sees FY Adj EPS $7.70-Adj EPS $8.10 >GILD

24. apr 2025, 20:02 UTC

Tulu

Gilead Sciences 1Q Rev $6.7B >GILD

11. apr 2025, 09:30 UTC

Peamised uudised

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

19. märts 2025, 14:50 UTC

Peamised uudised

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11. veebr 2025, 22:13 UTC

Market Talk
Tulu

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11. veebr 2025, 21:06 UTC

Tulu

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences Raises Dividend 2.6%>GILD

11. veebr 2025, 21:02 UTC

Tulu

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

Võrdlus sarnastega

Hinnamuutus

Gilead Sciences Inc. Prognoos

Hinnasiht

By TipRanks

9.79% tõus

12 kuu keskmine prognoos

Keskmine 116.79 USD  9.79%

Kõrge 140 USD

Madal 89 USD

Põhineb 24 Wall Streeti analüütiku instrumendi Gilead Sciences Inc. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

24 ratings

18

Osta

6

Hoia

0

Müü

Tehniline skoor

By Trading Central

105 / 106.5Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Very Strong Bearish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.